Sociedad Española de Neurología (SEN)

The Sociedad Española de Neurología (SEN) is the Spanish Society of Neurology, a professional organization dedicated to the study and advancement of neurology in Spain. While the provided articles don't directly mention SEN, they touch on topics highly relevant to the organization's focus. The first article discusses research linking optimism to a reduced risk of dementia, a key area of neurological study. The second highlights the availability in Spain of Skyclaris (omaveloxolona), the first drug specifically for Friedreich's ataxia, marking a significant advancement in treating this neurological disorder. SEN's relevance lies in its role in disseminating such research findings and clinical advancements to its members, influencing neurological practice and patient care in Spain. SEN likely plays a role in educating neurologists about new treatments like Skyclaris and promoting awareness of preventative measures for neurological conditions like dementia.